Critical Cellular Player Controlling HIV Reproduction in Immune Cells Identified

University of California, San Diego, School of Medicine researchers report the first genome-wide expression analysis of long noncoding RNA (lncRNA) in HIV-infected macrophages that promote tissue inflammation, stimulate the immune system, and rid the body of foreign debris. In general, lncRNAs do not encode the recipe for proteins the way other RNAs do, but instead help control which genes are turned “on” or “off” in a cell.

Enanta Gets Additional $9.2M toward Biodefense Antibiotic Development

NIAID is providing additional funding of $9.2 million to its existing contract with Enanta Pharmaceuticals to fund development for a new class of bridged bicyclic antibiotics called bicyclolides.

Gilead Partnering with China on Trial of Remdesivir as Coronavirus Treatment

Gilead Sciences will partner with Chinese health authorities on a randomized, controlled trial designed to assess its antiviral drug candidate remdesivir (GS-5734) as a potential treatment for 2019-nCoV novel coronavirus.

Xencor and Novo Nordisk Ink Bispecific Antibodies Deal

Xencor could receive up to $175 million in upfront payments, research support, and preclinical and clinical development, regulatory and sales milestones, in addition to future royalties.

Cold Genesys Buys BioSante’s Oncolytic Virus Technology

BioSante took a 19.9% stake in Cold Genesys and will get milestones and royalties.

Sequenta Scores $13M Series B Financing

PCR-based assays are designed to measure antigen receptor sequences of WBCs.

Allergan and AstraZeneca Commit to Antibiotic Development Deal

Allergan and AstraZeneca work on development and commercialization of antibiotic treatment for resistant microbes.

Sage, Washington University to Develop GABA Receptors for Anesthesia

Sage Therapeutics is now in a license agreement with Washington University in St. Louis to develop and commercialize novel small molecule GABAA receptor allosteric...

Novartis to Exploit Nuevolution Platform for Drug Discovery

Novartis enlisted the help of Danish drug discovery company Nuevolution to identify small molecule leads against specific drug targets. Nuevolution will use its fragment-based...

Common Cold Foiled If It Cannot Exploit Host Protein

Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases. The protein, an actin histidine methyltransferase called SET domain containing 3 (SETD3), was identified in a CRISPR screen and confirmed to be essential to viral pathogenesis in cultured cells and mouse models. Curiously, when viruses use SETD3, they neglect the part needed for enzymatic function.

Recently Featured

Scroll Up